Avalidated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

Blood

Volumn 109, Issue 6, 2007, Pages 2276-2284

  Shaughnessy Jr , John D ^a   Zhan, Fenghuang ^a   Burington, Bart E ^b   Huang, Yongsheng ^a   Colla, Simona ^a   Hanamura, Ichiro ^a   Stewart, James P ^a   Kordsmeier, Bob ^a   Randolph, Christopher ^a   Williams, David R ^a   Xiao, Yan ^a   Xu, Hongwei ^a   Epstein, Joshua ^a   Anaissie, Elias ^a   Krishna, Somashekar G ^a   Cottler Fox, Michele ^a   Hollmig, Klaus ^a   Mohiuddin, Abid ^a   Pineda Roman, Mauricio ^a   Tricot, Guido ^a   Van Rhee, Frits ^a   Sawyer, Jeffrey ^a   Alsayed, Yazan ^a   Walker, Ronald ^a   Zangari, Maurizio ^a   Crowley, John ^b   Barlogie, Bart ^a   more..

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 1Q; CONTROLLED STUDY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; UPREGULATION; BIOLOGICAL MODEL; CHROMOSOME 1; CHROMOSOME MAP; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MULTIGENE FAMILY; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR; SURVIVAL RATE;

AGED; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, GENETIC; MULTIGENE FAMILY; MULTIPLE MYELOMA; RECURRENCE; RISK FACTORS; SURVIVAL RATE;

EID: 33947217497     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-038430     Document Type: Article

References (31)

1. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12:960-969.
2. Wuilleme S, Robillard N, Lode L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2002;19:275-278.
3. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44:194-203.
4. Gutierrez NC, Garcia JL, Hernandez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood. 2004;104:2661-2666.
5. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of MM: a workshop report. Cancer Res. 2004;64:1546-1558.
6. Carrasco D, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9:313-325.
7. Shaughnessy J, Barlogie, B. Interpreting the molecular biology and clinical behavior of multiple myeloma through global gene expression profiling. Immunol Rev. 2003;94:140-163.
8. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nature Rev Cancer. 2002;2:175-187.
9. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-2028.
10. Avet-Loiseau H, Andree-Ashley LE, Moore D, et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer. 1997;19:124-133.
11. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91:1732-1741.
12. Le Baccon P, Leroux D, Dascalescu C, et al. Novel evidence of a role for chromosome 1 peri-centric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer. 2001;32:250-64.
13. Sawyer JR, Tricot G, Lukacs JL, et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer. 2005;42:95-106.
14. Rosinol L, Carrio A, Blade J, et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol. 2005;130:729-732.
15. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood. 2006;16: Epub ahead of print.
16. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
17. NIH Gene Expression Omnibus. Available at http://www.ncbi.nlm.nih.gov/ geo. Accessed June 1, 2006.
18. Storey JD, Tibshirani R. Statistical significance for genome wise studies. Proc Natl Acad Sci U S A. 2003;100:9440-9445.
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481,
20. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
21. O'Quigley J, Xu R, Stare J. Explained randomness in proportional hazards models. Stat Med. 2005;24:479-489.
22. R Development Core Team. A language and environment for statistical computing. Vienna, Austria. 2004. (ISBM 3-900051-07-0) Available at http://www.R-project.org. Accessed June 2005.
23. Rao CR. Linear statistical inference and its application. Wiley, NY; 1973.
24. Greipp P, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
25. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in MM treated with Total Therapy I: interpreted in the context of gene expression profiling. Blood. 2003;101:3849-3856.
26. Kapanadze B, Kashuba V, Baranova A, et al. A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5. FEBS Lett. 1998;426:266-270.
27. Itoyama T, Nanjungud G, Chen W, et al. Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer. 2002;35:318-328.
28. Lu YJ, Hing S, Williams R, et al. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet. 2002;360:385-386.
29. Hattinger CM, Potschger U, Tarkkanen M, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer. 2002;86:1763-1769.
30. Cheng KW, Lahad JP, Kuo WL, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004;10:1251-2156.
31. Zudaire I, Odero MD, Caballero C, et al. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology. 2002; 40:547-555.